These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29923692)

  • 1. Mapping of the available standards against the regulatory needs for nanomedicines.
    Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies.
    Urbán P; Liptrott NJ; Bremer S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1546. PubMed ID: 30556649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Main trends of immune effects triggered by nanomedicines in preclinical studies.
    Halamoda-Kenzaoui B; Bremer-Hoffmann S
    Int J Nanomedicine; 2018; 13():5419-5431. PubMed ID: 30271138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicines and Nanosimilars: Looking for a New and Dynamic Regulatory "Astrolabe" Inspired System.
    Demetzos C; Kavatzikidou P; Pippa N; Stratakis E
    AAPS PharmSciTech; 2020 Jan; 21(2):65. PubMed ID: 31933006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory aspects on nanomedicines.
    Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
    Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines: From Bench to Bedside and Beyond.
    Havel H; Finch G; Strode P; Wolfgang M; Zale S; Bobe I; Youssoufian H; Peterson M; Liu M
    AAPS J; 2016 Nov; 18(6):1373-1378. PubMed ID: 27480318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation.
    Halamoda-Kenzaoui B; Vandebriel RJ; Howarth A; Siccardi M; David CAW; Liptrott NJ; Santin M; Borgos SE; Bremer-Hoffmann S; Caputo F
    J Control Release; 2021 Aug; 336():192-206. PubMed ID: 34126169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
    Dri DA; Rinaldi F; Carafa M; Marianecci C
    Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
    Mühlebach S; Borchard G; Yildiz S
    Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties.
    Nijhara R; Balakrishnan K
    Nanomedicine; 2006 Jun; 2(2):127-36. PubMed ID: 17292125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of nanomedicines in the EU: distilling lessons from the pediatric and the advanced therapy medicinal products approaches.
    Chowdhury N
    Nanomedicine (Lond); 2010 Jan; 5(1):135-42. PubMed ID: 20025470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are existing standard methods suitable for the evaluation of nanomedicines: some case studies.
    Gioria S; Caputo F; Urbán P; Maguire CM; Bremer-Hoffmann S; Prina-Mello A; Calzolai L; Mehn D
    Nanomedicine (Lond); 2018 Mar; 13(5):539-554. PubMed ID: 29381129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Standards and Analytical Science for Nanoenabled Medical Products.
    Nelson BC; Minelli C; Doak SH; Roesslein M
    Annu Rev Anal Chem (Palo Alto Calif); 2020 Jun; 13(1):431-452. PubMed ID: 32084321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
    Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
    Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nanomedicines alliance: an industry perspective on nanomedicines.
    Malinoski FJ
    Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives.
    Souto EB; Blanco-Llamero C; Krambeck K; Kiran NS; Yashaswini C; Postwala H; Severino P; Priefer R; Prajapati BG; Maheshwari R
    Acta Biomater; 2024 May; 180():1-17. PubMed ID: 38604468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial intelligence aids in development of nanomedicines for cancer management.
    Tan P; Chen X; Zhang H; Wei Q; Luo K
    Semin Cancer Biol; 2023 Feb; 89():61-75. PubMed ID: 36682438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging communities in the field of nanomedicine.
    Halamoda-Kenzaoui B; Baconnier S; Bastogne T; Bazile D; Boisseau P; Borchard G; Borgos SE; Calzolai L; Cederbrant K; Di Felice G; Di Francesco T; Dobrovolskaia MA; Gaspar R; Gracia B; Hackley VA; Leyens L; Liptrott N; Park M; Patri A; Roebben G; Roesslein M; Thürmer R; Urbán P; Zuang V; Bremer-Hoffmann S
    Regul Toxicol Pharmacol; 2019 Aug; 106():187-196. PubMed ID: 31051191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized Nanomedicine: A Revolution at the Nanoscale.
    Fornaguera C; García-Celma MJ
    J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29023366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.